CA3196642A1 - Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof - Google Patents
Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereofInfo
- Publication number
- CA3196642A1 CA3196642A1 CA3196642A CA3196642A CA3196642A1 CA 3196642 A1 CA3196642 A1 CA 3196642A1 CA 3196642 A CA3196642 A CA 3196642A CA 3196642 A CA3196642 A CA 3196642A CA 3196642 A1 CA3196642 A1 CA 3196642A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- compound
- group
- reaction
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B49/00—Grignard reactions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020904060A AU2020904060A0 (en) | 2020-11-06 | Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof | |
| AU2020904060 | 2020-11-06 | ||
| PCT/AU2021/051310 WO2022094668A1 (en) | 2020-11-06 | 2021-11-05 | Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3196642A1 true CA3196642A1 (en) | 2022-05-12 |
Family
ID=81458249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3196642A Pending CA3196642A1 (en) | 2020-11-06 | 2021-11-05 | Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230416243A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4240740A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023548368A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230154789A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116981461A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021374232A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3196642A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2023001300A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL302671A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023004940A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022094668A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026509196A (ja) * | 2023-03-02 | 2026-03-17 | アクチノゲン メディカル リミテッド | アザ二環式ヘテロアリール化合物を調製するための流動化学プロセス |
| CN121969372A (zh) * | 2023-10-03 | 2026-05-01 | 射线质医疗有限公司 | 片剂制剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1732552A4 (en) * | 2004-01-20 | 2007-12-19 | Merck & Co Inc | 2,6-DISUBSTITUTED PIPERIDINES AS MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY |
| MY145633A (en) * | 2006-03-01 | 2012-03-15 | Theravance Inc | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| ES2366058T3 (es) * | 2006-03-01 | 2011-10-14 | Theravance, Inc. | Compuestos de 8-azabiciclo[3.2.1]octano como antagonistas de los receptores opioides mu. |
| CA2738453C (en) * | 2008-10-23 | 2017-07-04 | Boehringer Ingelheim International Gmbh | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use |
| DK2477983T3 (en) * | 2009-09-16 | 2015-06-29 | Univ Edinburgh | (4-phenyl-piperidin-1-yl) - [5-1H-pyrazol-4-yl) -thiophene-3-yl] -METHANONFORBINDELSER AND THEIR USE |
| AU2010331927B2 (en) * | 2009-12-17 | 2013-10-10 | Merck Canada Inc. | Aminopyrimidines as Syk inhibitors |
| WO2011090935A1 (en) * | 2010-01-19 | 2011-07-28 | Merck Sharp & Dohme Corp. | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS |
| BR112012027640B1 (pt) * | 2010-04-29 | 2021-08-03 | The University Of Edinburgh | Composto, composição farmacêutica, e, métodos de preparar uma composição farmacêutica, de inibir a função da 11beta-hidroxiesteroide desidrogenase do tipo 1 |
-
2021
- 2021-11-05 KR KR1020237018659A patent/KR20230154789A/ko active Pending
- 2021-11-05 AU AU2021374232A patent/AU2021374232A1/en active Pending
- 2021-11-05 EP EP21887915.3A patent/EP4240740A4/en active Pending
- 2021-11-05 IL IL302671A patent/IL302671A/en unknown
- 2021-11-05 MX MX2023004940A patent/MX2023004940A/es unknown
- 2021-11-05 WO PCT/AU2021/051310 patent/WO2022094668A1/en not_active Ceased
- 2021-11-05 CN CN202180088882.XA patent/CN116981461A/zh active Pending
- 2021-11-05 US US18/252,025 patent/US20230416243A1/en active Pending
- 2021-11-05 JP JP2023526903A patent/JP2023548368A/ja active Pending
- 2021-11-05 CA CA3196642A patent/CA3196642A1/en active Pending
-
2023
- 2023-05-04 CL CL2023001300A patent/CL2023001300A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4240740A4 (en) | 2024-12-11 |
| US20230416243A1 (en) | 2023-12-28 |
| CN116981461A (zh) | 2023-10-31 |
| EP4240740A1 (en) | 2023-09-13 |
| IL302671A (en) | 2023-07-01 |
| MX2023004940A (es) | 2023-09-12 |
| AU2021374232A9 (en) | 2024-09-26 |
| WO2022094668A1 (en) | 2022-05-12 |
| CL2023001300A1 (es) | 2024-01-05 |
| JP2023548368A (ja) | 2023-11-16 |
| KR20230154789A (ko) | 2023-11-09 |
| AU2021374232A1 (en) | 2023-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2956288T3 (es) | Métodos y productos intermedios para preparar un compuesto terapéutico útil en el tratamiento de infección vírica por Retroviridae | |
| US20240059678A1 (en) | Synthesis Method for Aminopyrimidine FAK Inhibitor Compound | |
| TW201713652A (zh) | 雜環化合物的合成 | |
| CN102329325B (zh) | 吡咯并嘧啶酮类dpp-iv抑制剂 | |
| CN106946917A (zh) | 一种jak抑制剂巴瑞替尼及其中间体的新合成方法 | |
| EP3766869A1 (en) | Simple preparation method for avibactam | |
| EP3733648B1 (en) | Method for preparing 5r-benzyloxyaminopiperidin-2s-carboxylic acid or derivative thereof | |
| US11926633B2 (en) | Synthesis methods for upadacitinib and intermediate thereof | |
| US20230416243A1 (en) | Process for Preparing Heterocyclic Methanone Compounds and AZA-Bicyclo Intermediates Thereof | |
| JP2026082843A (ja) | 合成方法及び中間体 | |
| CN102725288A (zh) | 用于制造6-取代的1-甲基-1h-苯并咪唑衍生物的方法和所述方法的中间体 | |
| EP3543236A1 (en) | Method for preparing avibactam intermediate | |
| EP2841419A1 (en) | Crystalline forms of saxagliptin | |
| CN108658851B (zh) | 2-氯-3-甲基-6-酰基氨基吡啶及其制备方法和用途 | |
| US20210147466A1 (en) | Improved processes for the preparation of guadecitabine and intermediates thereof | |
| CN104876872A (zh) | 一种制备1-叔丁氧基羰基-3-羟甲基吲唑的方法及应用 | |
| US9085569B2 (en) | 1,2,4-oxadiazol derivatives, process for their preparation and use thereof as intermediates in the preparation of indolic alkaloids | |
| CA3268617A1 (en) | Synthesis methods and intermediates | |
| US20260001882A1 (en) | Process for preparing bicyclic glycine-proline compounds and monocyclic glycine-proline intermediates thereof | |
| US20250304538A1 (en) | Process of preparing remibrutinib substantially free of nitrosamine impurity | |
| CN105121417B (zh) | 经取代噻唑基乙酸三乙胺盐的结晶型 | |
| CN102924332B (zh) | N-p-双酸氨基酸单酯的合成工艺改进 | |
| JP2013010735A (ja) | 1,2,4−トリアゾール化合物及びグアニジン誘導体の合成方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240902 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240902 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240902 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251006 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251006 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251104 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251104 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251104 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260105 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260105 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260105 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260105 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260105 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260122 |